Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Actual left/right wing discussion -- Ignore unavailable to you. Want to Upgrade?

To: CapitalistHogg™ who wrote (4854)	11/16/2006 10:57:49 AM
From: Wharf Rat	Respond to of 10087

You can start with MS... Sativex From Wikipedia, the free encyclopedia Sativex is an oromucosal (mouth) spray developed by the UK company GW Pharmaceuticals for multiple sclerosis patients, who can use it to alleviate neuropathic pain and spasticity. Sativex is distinct from all other pharmaceutically produced cannabinoids currently available because it is derived from botanical material, rather than a solely synthetic process. Sativex is a pharmaceutical product standardised in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The product is formulated as an oromucosal spray which is administered by spraying into the mouth. Each spray of Sativex delivers a fixed dose of 2.7mg THC and 2.5mg CBD. Approved by Health Canada under a license with conditions (NOC/c) for prescription use in April 2005, Sativex is the world's first pharmaceutical prescription medicine derived from the cannabis plant. It is available in the UK as an unlicensed medicine imported from Canada to satisfy its prescription to individual patients. It is also available in Catalonia, Spain, for 600 patients suffering from multiple sclerosis and a number of other conditions under a compassionate access programme (130 of the patients will be people with multiple sclerosis, a further 130 will be patients with neuropathic pain arising from a range of medical conditions, 40 will be suffering from anorexia and malnutrition caused by AIDS, and the remaining 300 will be cancer patients undergoing chemotherapy and suffering from nausea and vomiting). In December 2005, GW and the Spanish pharmaceutical company Almirall announced an exclusive agreement for Almirall to market Sativex in Europe (excluding the UK). In the UK and Canada, Bayer HealthCare have been appointed as exclusive distributors. In early 2006, Sativex received permission from the US regulatory authority, the FDA, to enter directly into late stage Phase III trials in the US. In late 2006, GW Pharmaceuticals will begin its first Phase III trial in the US for cancer patients. The 250-patient, double-blind, randomized, placebo-controlled study will evaluate the effect of Sativex in relieving average daily pain, reducing the use of breakthrough opioid medications, improving the quality of sleep and relevant aspects of quality of life among other outcome measures. In clinical trials, Sativex has generally been well tolerated. Compare dronabinol (marketed as Marinol), a synthetic version of THC. en.wikipedia.org =============== GW pharmaceuticals is developing a portfolio of cannabis medicines the first of which, “Sativex® Oromucosal Spray”, received an Approval with Conditions from Health Canada in April 2005 for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in Multiple Sclerosis (MS). Sativex® was launched in Canada in June 2005. Sativex® has been licensed to Bayer in the UK and to Almirall in the rest of European countries, although regulatory approval has not yet been granted in any of those territories. Doctors wishing to prescribe Sativex® as an unlicensed medicine may do so on a named patient basis where local medical and narcotic control regulations allow. gwpharm.com

To: CapitalistHogg™ who wrote (4854)	11/16/2006 1:06:07 PM
From: Brumar89	Read Replies (1) \| Respond to of 10087

Either would be okay, but I'm interested in studies / surveys of regular habitual pot smokers. Not pot itself, but the people who use it heavily long-term. ------------------------------- It's been pointed out to me our discussion on this subject has been followed by some folks who want to comment but are too snobbish to take part in the discussion: Message 23012810 Message 23012841 siliconinvestor.com I see no reason not to address comments directed at my posts so ... The middle post of the posts above by eleutheria to Dale Baker has a survey which is presented as evidence of what pot smokers are like. Amazingly it is a 39 year old study from the summer of 1967!!!!! Good grief! Based on an unscientific sample drawn from elite sections of NYC young people. The median age of my informants was twenty-two, with slightly over one-fifth in their teens (21 percent), and less than a tenth ( 7 percent) were thirty or over. At about the same time I was conducting my survey, The East Village Other, a New York underground newspaper whose 25,000 readers include a considerable percentage of drug users, did a study of its own. In the April 1967 issue, EVO included a fill-out, mail-in questionnaire on its readers' drug use. ..... 3. During the period of the interviews I conducted (July and August 1967) 1967 was smack dab in the period pot started to become widely used among American young people. At the time there were hardly any long-term pot smokers available for study It's also worth noting the "researcher" is a fellow whose career has specialized in reseraching "deviance" and who apparently thinks its good scholarship to take part in the activities studied: Erich Goode is an American sociologist. Goode specializes in the sociology of deviance. He has written a number of books on the field of deviance in general, as well as on specific deviant topics. ..... As a sociologist, Goode relies heavily on informants for his research. For example, Goode consulted with and interviewed actual drug users for his books on drugs. In 1999, Goode admitted through the sociology journal circuit that he had engaged in sexual intercourse with many of his deviant informants, and discussed how this influenced his perspective on the subject he was studying. This caused a firestorm of articles defending or denouncing his work [2]. Retrieved from "http://en.wikipedia.org/wiki/Erich_Goode" I expect he was high most of the time he was researching drug use and his survey was of the people he was smoking with, sleeping with, whatever. Putting forward this in 2006 as a resource for information on drug users is pathetic! If this is the best reference material on pot smokers available, then there must be no meaningful reference material. If so, I wonder why that is?